Evidence comparison
Tirzepatide vs. semaglutide: evidence fields
This comparison summarizes approved indications, trial populations, and evidence gaps without recommending one medicine over another.
| Field | Tirzepatide | Semaglutide |
|---|---|---|
| Mechanism | Dual GIP/GLP-1 agonist | GLP-1 agonist |
| Approved obesity indication (U.S.) | Approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity (Zepbound). | Approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity (Wegovy). |
| Women's representation | SURMOUNT-1: 2,539 enrolled, ~67.5% female. | STEP-1: 1,961 enrolled, ~63.2% female. |
| Sex-analysis quality | Prespecified subgroup analysis; FDA reported a significant treatment-by-sex interaction, but the trials were not powered for sex comparison. | Prespecified subgroup analysis reported; no statistically significant sex interaction. |
| Pregnancy/lactation data | Limited; stop at least 2 months before a planned pregnancy and when pregnancy is recognized. | Limited; stop at least 2 months before a planned pregnancy and when pregnancy is recognized. |
Sources
Primary records
- regulatory label
U.S. FDA-approved label for tirzepatide (Zepbound).
- regulatory label
U.S. FDA-approved label for semaglutide 2.4 mg (Wegovy) for chronic weight management.
- peer reviewed article · New England Journal of Medicine · 2022-07-21
Phase 3 trial of tirzepatide in adults with obesity or overweight without diabetes (NCT04184622).
- peer reviewed article · New England Journal of Medicine · 2021-03-18
Phase 3 trial of semaglutide 2.4 mg for chronic weight management.
Medical disclaimer: Her Health Peptides publishes educational, source-linked summaries. We do not provide individualized medical advice, diagnosis, or treatment recommendations. Always talk with a licensed clinician about your specific situation, especially if you are pregnant, breastfeeding, planning pregnancy, or taking other medicines.